Bright Peak Therapeutics raised $90 million in a Series C financing round led by Johnson & Johnson Innovation. Proceeds from the Series C financing will be used to advance BPT567 into a Phase 1/2a clinical trial and accelerate a pipeline of next-generation immunotherapies. The Phase 1/2a study in solid tumors is expected to begin in 2H 2024..

。C系列融资的收益将用于将BPT567推进1/2a期临床试验，并加速下一代免疫疗法的开发。实体瘤的1/2a期研究预计将于2024年下半年开始。。

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies to treat cancer and other diseases. “We are now well positioned to bring much needed innovation to the field of anti-PD-1 immune-checkpoint inhibition and look forward to advancing our lead program into the clinic later this year across multiple tumor types” said Fredrik Wiklund, Chief Executive Officer of Bright Peak..

Bright Peak Therapeutics是一家生物技术公司，致力于开发多功能免疫疗法组合，以治疗癌症和其他疾病。Bright Peak首席执行官弗雷德里克·维克隆德（Fredrik Wiklund）表示：“我们现在处于有利地位，可以在抗PD-1免疫检查点抑制领域带来急需的创新，并期待着在今年晚些时候将我们的领先项目推进多种肿瘤类型的临床。”。。

The round was led by Johnson & Johnson Innovation – JJDC, with participation from additional new investors Venrock, KB Investment, and Northleaf Capital Partners. Existing investors participating in the round include founding investor Versant Ventures along with Fidelity Management & Research Company, RA Capital Management, Qatar Investment Authority, Invus, Alexandria Venture Investments, and an undisclosed leading healthcare investment fund..

这一轮由强生创新（JJDC）牵头，其他新投资者Venrock、KB Investment和Northleaf Capital Partners也参与了。参与本轮投资的现有投资者包括创始投资者Versant Ventures，以及Fidelity Management&Research Company、RA Capital Management、卡塔尔投资局、Invus、Alexandria Venture Investments和一家未披露的领先医疗保健投资基金。。

Bright Peak’s lead program BPT567 is a first-in-class PD1-IL18 immunoconjugate designed to provide simultaneous blockade of the PD(L)-1 checkpoint pathway and targeted delivery of IL-18 signaling.

。

In preclinical models, BPT567 induced profound synergistic anti-tumor activity by blocking PD-1 and specifically targeting the potent proinflammatory effects of IL-18 to effector T cells in the tumor microenvironment (TME) with more limited activation of immune cells in the periphery.

在临床前模型中，BPT567通过阻断PD-1并特异性靶向IL-18对肿瘤微环境（TME）中效应T细胞的有效促炎作用而诱导了显着的协同抗肿瘤活性，而外周免疫细胞的激活更为有限。

Bright Peak’s chemical protein synthesis technology was initially developed by our Founders Vijaya Pattabiraman and Jeffrey Bode at ETH Zürich and the company was seeded and launched by Versant Ventures at the firm’s Ridgeline Discovery laboratories. The company is based in Allschwil (BS) and San Diego, CA..

Bright Peak的化学蛋白质合成技术最初是由我们的创始人Vijaya Pattabiraman和ETH Zürich的Jeffrey Bode开发的，该公司是由Versant Ventures在该公司的Ridgeline Discovery laboratories播种并启动的。该公司位于Allschwil（BS）和加利福尼亚州圣地亚哥。。